pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
BRISTOL MYERS SQUIBB · news · pharmadog
← back to BRISTOL MYERS SQUIBB
News mentioning BRISTOL MYERS SQUIBB
305
stories
Aug 6, 26
Cardiac drug developer Braveheart banks more than $382M in IPO
biopharma dive
Aug 5, 26
No deal between AstraZeneca and BMS, senior source insists: Reuters
biospace
Aug 5, 26
Chaotic adcomms threaten to derail FDA’s bid to renew trust after Makary, Prasad
biospace
Aug 5, 26
STAT+: Pharmalittle: We’re reading about a Medicare pilot and orphan drugs, Pfizer cutbacks, and more
stat
Aug 5, 26
Merger talks between AstraZeneca, Bristol Myers are off — report
endpoints
Aug 5, 26
A COPD drug from China draws $115M in venture funding
biopharma dive
Aug 5, 26
Rumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcomms
biospace
Aug 5, 26
5 NextGen winners who went public this year (and which ones are hiring)
biospace
Aug 5, 26
4 potential biotech M&A targets, plus a pretty sure bet from J&J
biospace
Aug 4, 26
As portfolio erodes, BMS stands to gain a lot from rumored AstraZeneca merger
biospace
Aug 4, 26
Icon inks Anthropic partnership to deploy Claude into clinical trials
fiercebiotech
Aug 4, 26
Post-Hoc Live: Who wants an AstraZeneca-Bristol Myers megadeal?
endpoints
Aug 3, 26
Biopharma industry questions potential AstraZeneca, Bristol Myers merger
endpoints
Aug 3, 26
An AstraZeneca-Bristol Myers megamerger? Wall Street isn’t thrilled.
biopharma dive
Aug 3, 26
BioNTech taps Sobi executive Oelkers as its next CEO
biopharma dive
Aug 3, 26
Supernus and Indivior merge to create CNS mega-company with 11 approved drugs
biospace
Aug 3, 26
STAT+: Pharmalittle: We’re reading about AstraZeneca-Bristol merger talks, a revised 340B plan, and more
stat
Aug 3, 26
BioNTech picks Sobi CEO Oelkers to lead as founders plot new mRNA biotech
biospace
Aug 3, 26
‘Unlikely’ AstraZeneca-BMS mega-merger would be largest pharma deal ever
biospace
Aug 3, 26
BlossomHill eyes $112M IPO harvest to bankroll potential Tagrisso challenger
fiercebiotech
Aug 3, 26
After 5-month wait, BioNTech announces Sobi CEO will take on top job at mRNA company
fiercebiotech
Aug 3, 26
Editor’s Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad idea
fiercebiotech
Aug 2, 26
AstraZeneca, Bristol Myers in talks about merger — report
endpoints
Jul 31, 26
Trump administration tries again to institute rebates in 340B
biopharma dive
Jul 31, 26
Moderna maintains 10% growth target despite Phase 3 norovirus miss
biospace
Jul 31, 26
Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOs
biopharma dive
Jul 31, 26
Ratio collects $70M for its radiopharmaceutical trials; Vogenx plans $67M IPO
endpoints
Jul 30, 26
Replimune overcomes ‘messy data’ to secure positive adcomm vote for melanoma therapy
biospace
Jul 30, 26
Replimune melanoma drug wins support of FDA panel
biopharma dive
Jul 30, 26
Replimune’s twice-rejected melanoma drug prevails in FDA adcomm
fiercebiotech
← prev
page 7 of 11
next →
